58 results on '"Krüger, William"'
Search Results
2. Implementation of Palliative Care in Clinical Practice in German Units for Allogeneic Stem Cell Transplantation: A Nationwide Survey.
- Author
-
Krüger, William, Buchhold, Britta, Nonnenberg, Dennis, Neumann, Thomas, Schneidewind, Laila, and Schmidt, Christian A.
- Abstract
Allogeneic stem cell transplantation (alloSCT) is a curative therapy for otherwise fatal diseases, however it is associated with a considerable morbidity and mortality. In consequence, it can be assumed that a considerable percentage of patients would benefit from high-quality palliative care (PC) during their course of disease. To assess the standard of PC in German transplant centers, a questionnaire was sent out to all German centers recognized from the EBMT membership list and the annually ZKRD report (n = 52). The response rate was not as high as expected with n = 27 (51,9%), even after reminding by phone calls or by e-mails. In brief, palliative care after allogeneic stem cell transplantation shows a wide variation in Germany. This is true for structures, processes and measures. A national standard for SCT-patients has not been established so far and there are no pre-conditions concerning palliative care after alloSCT for a certification by the EBMT according the JACIE standards. There is a considerable need for a crosslinking of alloSCT with PC. Clear standards should be established by the scientific societies concerning personnel, structure and processes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
- Author
-
Hernández‐Boluda, Juan‐Carlos, Pereira, Arturo, Kröger, Nicolaus, Cornelissen, Jan J., Finke, Jürgen, Beelen, Dietrich, de Witte, Moniek, Wilson, Keith, Platzbecker, Uwe, Sengeloev, Henrik, Blaise, Didier, Einsele, Hermann, Sockel, Katja, Krüger, William, Lenhoff, Stig, Salaroli, Adriano, Martin, Hans, García‐Gutiérrez, Valentín, Pavone, Vicenzo, and Alvarez‐Larrán, Alberto
- Published
- 2021
- Full Text
- View/download PDF
4. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
- Author
-
Krüger, William H., Hirt, Carsten, Basara, Nadezda, Sayer, Herbert G., Behre, Gerhard, Fischer, Thomas, Grobe, Norbert, Maschmeyer, Georg, Neumann, Thomas, Schneidewind, Laila, Niederwieser, Dietger, Dölken, Gottfried, and Schmidt, Christian A.
- Subjects
MANTLE cell lymphoma ,STEM cell transplantation ,NON-Hodgkin's lymphoma ,CELL transplantation ,OVERALL survival ,LYMPHOMA treatment ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,HOMOGRAFTS ,GRAFT versus host disease ,CLINICAL trials ,DOXORUBICIN ,RESEARCH methodology ,PROGNOSIS ,IMMUNOSUPPRESSION ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,QUALITY of life ,CYCLOPHOSPHAMIDE ,PREDNISONE ,LYMPHOMAS ,VINCRISTINE ,LONGITUDINAL method - Abstract
Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell transplantation (alloSCT) is associated with a higher early mortality, but can cure MCL. To investigate alloSCT for therapy of MCL, we conducted two prospective trials for de novo MCL (OSHO#74) and for relapsed or refractory MCL (OSHO#60). Fifteen and 24 patients were recruited, respectively. Induction was mainly R-DHAP alternating with R-CHOP. Conditioning was either Busulfan/Cyclophosphamide or Treosulfan/Fludarabin. Either HLA-identical siblings or matched-unrelated donors with not more than one mismatch were allowed. ATG was mandatory in mismatched or unrelated transplantation. Progression-free survival (PFS) was 62% and overall survival (OS) was 68% after 16.5-year follow-up. Significant differences in PFS and OS between both trials were not observed. Patients below 56 years and patients after myeloablative conditioning had a better outcome compared to patients of the corresponding groups. Nine patients have died between day +8 and 5.9 years after SCT. Data from 7 long-term surviving patients showed an excellent Quality-of-life (QoL) after alloSCT. AlloSCT for MCL delivers excellent long-term survival data. The early mortality is higher than after autoSCT; however, the survival curves after alloSCT indicate the curative potential of this therapy. AlloSCT is a standard of care for all feasible patients with refractory or relapsed MCL and should offer to selected patients with de novo MCL and a poor risk profile. For defining the position of alloSCT in the therapeutic algorithm of MCL therapy, a randomized comparison of autoSCT and alloSCT is mandatory. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Summary.
- Author
-
Solves, Pilar, Lozano, Miquel, Zhiburt, Eugene, Anguita Velasco, Javier, Maria Pérez‐Corral, Ana, Monsalvo‐Saornil, Silvia, Yamazaki, Sho, Okazaki, Hitoshi, Selleng, Kathleen, Aurich, Konstanze, Krüger, William, Buser, Andreas, Holbro, Andreas, Infanti, Laura, Stehle, Gregor, Pierelli, Luca, Matteocci, Antonella, Rigacci, Luigi, De Vooght, Karen M. K., and Kuball, Jurgen H. E.
- Subjects
STEM cell transplantation ,PURE red cell aplasia ,RED blood cell transfusion ,BLOOD group incompatibility ,HEMATOPOIETIC stem cell transplantation ,BONE marrow transplantation - Abstract
Haematopoietic stem-cell transplantation (HSCT) is performed mainly in patients diagnosed with malignancies or some severe congenital diseases. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Patients with PRCA can become RBC transfusion dependent for a long period, suffering an important long-term iron overload, alloimmunization and transfusion reactions [15]. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
6. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Responses.
- Author
-
Solves, Pilar, Lozano, Miquel, Zhiburt, Eugene, Anguita Velasco, Javier, Maria Pérez‐Corral, Ana, Monsalvo‐Saornil, Silvia, Yamazaki, Sho, Okazaki, Hitoshi, Selleng, Kathleen, Aurich, Konstanze, Krüger, William, Buser, Andreas, Holbro, Andreas, Infanti, Laura, Stehle, Gregor, Pierelli, Luca, Matteocci, Antonella, Rigacci, Luigi, De Vooght, Karen M. K., and Kuball, Jurgen H. E.
- Subjects
PURE red cell aplasia ,STEM cell transplantation ,BLOOD transfusion reaction ,BLOOD groups ,RED blood cell transfusion ,BLOOD group incompatibility ,BLOOD cell count - Abstract
- We systematically monitor the efficacy of platelet transfusions by a post-transfusion platelet count at 20 h after transfusion. The efficacy of platelet transfusions is not routinely measured by a post-platelet transfusion increment (PPI), however if there are any concerns regarding the daily platelet counts (e.g. persisting low counts after prior transfusion such that the patient is requiring very frequent transfusions), we would perform platelet increment testing at 30-60 min post-transfusion. We advise monitoring of post-transfusion platelet counts (15-60 min post) in "high-use alert cases" (three consecutive days with >=1 platelet transfusion per day), or in the evaluation of immune-selected single donor apheresis platelets (to assess the in vivo efficacy of products which had been selected to circumvent the last known array of HLA- and/or HPA-specific antibodies). We systematically monitor the efficacy of platelet transfusions in patients undergoing HSCT by a post-transfusion platelet count about an hour after finishing the transfusion. At our institution, if a patient is independent of RBC transfusion for 90 days and no incompatible isohemagglutinins against the new RBC phenotype are detected in two consecutive blood samples, then the patient's native blood type is switched to the donor type for future transfusion. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
7. Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Krüger, William, Hakenberg, Oliver Walther, and Schmidt, Christian A.
- Subjects
BK virus ,ENZYME-linked immunosorbent assay ,CYSTITIS ,POLYMERASE chain reaction ,VIRAL replication ,CELL culture ,RABBIT diseases - Abstract
The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme‐linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL‐11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL‐11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 106 copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL‐11. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Does rehabilitation pose a risk to patients suffering from haemato‐oncological diseases? Results of a monocentric, retrospective analysis in Germany.
- Author
-
Kiefer, Thomas, Krahl, Dorothea, Kohlmann, Thomas, Nogai, Axel, Baurmann, Herrad, Schüler, Frank, Krüger, William, Wit, Maike, Pink, Daniel, Dietz, Marion, Völler, Heinz, Buhlert, Hermann, and Daeschlein, Georg
- Subjects
BLOOD diseases ,IMMUNOSUPPRESSION ,HEALTH outcome assessment ,PATIENT safety ,REHABILITATION centers ,TUMORS ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Objective: Patients suffering from haemato‐oncological diseases tend to have a weakened immune system after the end of their therapy. To avoid infections, patients are advised to limit contact with other people. This poses the question whether a stay at a rehabilitation facility can be recommended. Methods: We report about 134 rehabilitation stays of patients. Premature discontinuation of the rehabilitation stay was selected as the criterion for a serious complication during the rehabilitation, and the underlying reasons were analysed. Results: Compared to the discontinuation rates of patients suffering from solid tumours (2.4%), the percentage of haemato‐oncological patients ending prematurely their rehabilitation stay (8.2%) is significantly increased. This rises to 17.1% for patients who have undergone an allogeneic stem cell transplantation. The analysis of the discontinuation reasons revealed that they were not directly connected to the rehabilitation. Apart from the already known risk factors for premature termination of the rehabilitation stay, we have identified the period (days) between the last therapy and the beginning of the rehabilitation stay as a risk factor. Conclusions: We show for the first time that a rehabilitation stay does not pose additional risks for patients suffering from haemato‐oncological diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Nationwide survey of BK polyomavirus associated hemorrhagic cystitis in adult allogeneic stem cell transplantation among haematologists and urologists.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Kranz, Jennifer, Knoll, Florian, Pelzer, Alexandre, Schmidt, Christian, Krüger, William, Pelzer, Alexandre Egon, and Krüger, William
- Subjects
BK virus diseases ,CYSTITIS ,STEM cell transplantation ,GRAFT versus host disease ,DISEASES in adults ,PUBLIC health ,PATIENTS - Abstract
There are no epidemiological data on BK virus associated hemorrhagic cystitis (BKHC) in adult allogeneic stem cell transplantation in Germany available and associations with clinical conditions like GvHD are controversially discussed. Therefore, we conducted a nationwide survey among haematologists and urologists about this disease. We developed two questionnaires, one for haematologists (26 items) and one for urologists (20 items) concerning BKHC in adult allogeneic stem cell transplantation with epidemiological data and clinical implications. The survey was sent out at least three times to EBMT registered centres performing at least five transplantations a year, leading to 39 centres. The recruiting time was between January and June 2016. Total response rates were 76.9% among haematologists and 74.4% among urologists. BKHC seems to appear less frequent in this survey than it is described in the literature. Six deaths in the last 5 years due to this disease have been reported. Interestingly, haematologists as well as urologists mostly think that local therapy is most effective while 50.0% stated that there is no real effective oral or intravenous medication. Associations with other clinical conditions mentioned were heterogeneous, e.g. transplantation type, CMV reactivation, acute GvHD, nephropathy and worse clinical outcome. There was a significant discrepancy between haematologists and urologist concerning the association with acute GvHD (p = 0.004). We need prospective, multicentric clinical studies to evaluate local therapy and for developing a risk stratification model since this disease can be severe with morbidity and rarely mortality. In our opinion, this should be an interdisciplinary approach. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.
- Author
-
Ni, Ming, Wang, Lei, Yang, Mingya, Neuber, Brigitte, Sellner, Leopold, Hückelhoven-Krauss, Angela, Schubert, Maria-Luisa, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Wuchter, Patrick, Chen, Bao-an, Eckstein, Volker, Krüger, William, Yerushalmi, Ronit, Beider, Katia, Nagler, Arnon, Müller-Tidow, Carsten, Dreger, Peter, and Schmitt, Michael
- Subjects
KILLER cells ,GRAFT versus host disease ,PHOTOPHORES ,HEMATOPOIETIC stem cells ,CYTOKINES - Abstract
CD56
bri natural killer (NK) cells play an important role in the pathogenesis of graft-vs. -host disease (GVHD) and immune defense in the early period after allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) as an immunomodulating therapy has been widely used for GVHD treatment. However, the mechanism of action of ECP still remains to be elucidated, particularly the influence of ECP on NK cells. Thirty-four patients with steroid-refractory/resistant acute GVHD (aGVHD) ≥ °II and moderate to severe chronic GVHD (cGVHD) received ECP therapy. Patient samples obtained during intensive and long-term treatment were analyzed. Immunomonitoring with respect to cell phenotype and function was performed on rested peripheral blood mononuclear cells (PBMCs) using multiparametric flow cytometry. NK activity in terms of cytokine release was analyzed by intracellular cytokine staining after co-culture with K562 cells. Moreover, the proliferative capacity of NK cells, CD4+ , and CD8+ T cells was determined by carboxyfluorescein succinimidyl ester (CFSE) staining. Clinically, 75% of aGVHD and 78% of cGVHD patients responded to ECP therapy. Moreover, our data show that aGVHD, cGVHD patients and healthy donors (HDs) present distinct NK patterns: aGVHD patients have a higher frequency of CD56bri NK subsets with stronger NKG2D and CD62L expression, while CD56− CD16+ NK cells with higher expression of CD57 and CD11b stand out as a signature population for cGVHD. ECP therapy could significantly decrease CD56bri CD16− NK cells with shifting the quality from a cytotoxic to a regulatory pattern and additionally mature CD56dim NK cells via upregulation of CD57 in complete responding aGVHD patients. Moreover, ECP could keep the anti-viral and anti-leukemic effects intact via maintaining specialized anti-viral/leukemic CD57+ NKG2C+ CD56dim NK cells as well as remaining the quality and quantity of cytokine release by NK cells. The proliferative capacity of effector cells remained constant over ECP therapy. In conclusion, ECP represents an attractive option to treat GVHD without compromising anti-viral/leukemic effects. Shaping of CD56bri NK cell compartment by downregulating the cytotoxic subset while upregulating the regulatory subset contributes to the mechanisms of ECP therapy in aGVHD. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. Ruxolitinib for Therapy of Graft-versus-Host Disease.
- Author
-
Neumann, Thomas, Schneidewind, Laila, Weigel, Martin, Plis, Andrzej, Vaizian, Rem, Schmidt, Christian A., and Krüger, William
- Subjects
RUXOLITINIB ,GRAFT versus host disease prevention ,PROTEIN-tyrosine kinase inhibitors ,DISEASE relapse prevention ,DIARRHEA ,ENZYME inhibitors ,GRAFT versus host disease ,HEMOLYTIC-uremic syndrome ,STEROIDS ,TREATMENT effectiveness ,SEVERITY of illness index ,THERAPEUTICS - Abstract
Objective. Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality. There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids. Furthermore, some patients may have contraindications against CNI or high-dose steroids. Efficacy of ruxolitinib against GvHD has been described recently. Methods. Ruxolitinib was used for treatment of acute or chronic GvHD in eight patients. The patients either needed intensification of therapy or had contraindications against use of CNI or high-dose steroids. Results. Supplementation of therapy in acute GvHD with severe diarrhea with ruxolitinib was unsuccessful. All these patients died from acute GvHD. Introduction of ruxolitinib into therapy and relapse prophylaxis in other patients was successful in 4/4 cases (CR=3, PR=1). Indications for ruxolitinib were contraindications against CNI due to aHUS in two cases and the need for steroid sparing in two other cases. None of these patients suffered from diarrhea at the initiation of ruxolitinib. Conclusion. Ruxolitinib was effective for therapy of acute and chronic GvHD in higher lines in patients without severe diarrhea. Ruxolitinib could replace successfully CNI and high-dose steroids. Further investigations are necessary to define the position of ruxolitinib in GvHD-therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.
- Author
-
Wang, Lei, Ni, Ming, Hückelhoven-Krauss, Angela, Sellner, Leopold, Hoffmann, Jean-Marc, Neuber, Brigitte, Luft, Thomas, Hegenbart, Ute, Schönland, Stefan, Kleist, Christian, Sill, Martin, Chen, Bao-an, Wuchter, Patrick, Eckstein, Volker, Krüger, William, Hilgendorf, Inken, Yerushalmi, Ronit, Nagler, Arnon, Müller-Tidow, Carsten, and Ho, Anthony D.
- Abstract
Graft-vs.-host disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation, significantly affects the post-transplant morbidity and mortality. Systemic steroids remain the gold standard for the initial management of GvHD. However, up to 60% of patients will not sufficiently respond to steroids. Extracorporeal photopheresis (ECP), a cell-based immunotherapy, has shown good clinical results in such steroid-refractory/resistant GvHD patients. Given its immunomodulatory, but not global immunosuppressive and steroid-sparing capacity, ECP constitutes an attractive option. In the case of GvHD, the balance of immune cells is destroyed: effector cells are not any longer efficiently controlled by regulatory cells. ECP therapy may restore this balance. However, the precise mechanism and the impact of ECP on anti-viral/anti-leukemic function remain unclear. In this study, 839 ECP treatments were performed on patients with acute GvHD (aGvHD) and chronic GvHD (cGvHD). A comprehensive analysis of effector and regulatory cells in patients under ECP therapy included multi-parametric flow cytometry and tetramer staining, Luminex
TM -based cytokine, interferon-γ enzyme-linked immunospot, and chromium-51 release assays. Gene profiling of myeloid-derived suppressor cells (MDSCs) was performed by microarray analysis. Immunologically, modulations of effector and regulatory cells as well as proinflammatory cytokines were observed under ECP treatment: (1) GvHD-relevant cell subsets like CD62L+ NK cells and newly defined CD19hi CD20hi B cells were modulated, but (2) quantity and quality of anti-viral/anti-leukemic effector cells were preserved. (3) The development of MDSCs was promoted and switched from an inactivated subset (CD33− CD11b+ ) to an activated subset (CD33+ CD11b+ ). (4) The frequency of Foxp3+ CD4+ regulatory T cells (Tregs) and CD24+ CD38hi regulatory B cells was considerably increased in aGvHD patients, and Foxp3+ CD8+ Tregs in cGvHD patients. (5) Proinflammatory cytokines like IL-1β, IL-6, IL-8, and TNF-α were significantly reduced. In summary, ECP constitutes an effective immunomodulatory therapy for patients with steroid-refractory/resistant GvHD without impairment of anti-viral/leukemia effects. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
13. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
- Author
-
Ullmann, Andrew, Schmidt-Hieber, Martin, Bertz, Hartmut, Heinz, Werner, Kiehl, Michael, Krüger, William, Mousset, Sabine, Neuburger, Stefan, Neumann, Silke, Penack, Olaf, Silling, Gerda, Vehreschild, Jörg, Einsele, Hermann, Maschmeyer, Georg, Ullmann, Andrew J, Heinz, Werner J, Krüger, William, Vehreschild, Jörg Janne, and Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)
- Subjects
HEMATOPOIETIC stem cell transplantation ,COMMUNICABLE disease treatment ,ANTIBIOTIC prophylaxis ,COMPLICATIONS from organ transplantation ,TREATMENT effectiveness ,EVIDENCE-based medicine ,MEDICAL protocols - Abstract
Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus‐associated hemorrhagic cystitis following adult allogeneic stem cell transplantation—A systematic review.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Schmidt, Christian Andreas, and Krüger, William
- Subjects
INTRAVENOUS therapy ,INTRAVESICAL administration ,CYSTITIS ,HEMORRHAGE treatment ,POLYOMAVIRUS diseases ,BK virus ,STEM cell transplantation ,GRAFT versus host disease - Abstract
Abstract: Introduction: BK polyomavirus can lead to hemorrhagic cystitis (BKPyV‐HC) in allogeneic stem cell transplantation and therefore to increased morbidity. No causal therapy has been established yet. Cidofovir (CDV) is a nucleotide analog of cytosine that is active against various DNA viruses and it has been described for therapy of BKPyV‐HC using 2 admission routes: intravenous and intravesical. Methods: We performed a systematic review regarding the comparison of intravenous or intravesical cidofovir in the treatment of BKPyV‐HC following adult allogeneic stem cell transplantation. Since there is a lack of randomized controlled trials, we considered all kinds of studies for this review. Due to heterogeneity of the data, we were not able to perform a meta‐analysis, so the results are shown descriptively. Results: The literature search for primary studies yielded 232 results. Finally, 9 studies where considered which included a total of 189 adult patients with BKPyV‐HC after allogeneic stem cell transplantation. We could only identify retrospective studies for this review. A total of 172 patients received intravenous CDV, 17 patients received intravesical CDV, and 2 patients received CDV in both admission routes. In 68.0% of the cases, a complete response for intravenous CDV was documented and in 88.2% for intravesical CDV. Interestingly, no kidney toxicity was mentioned in intravesical CDV. 9.3% of the intravenously treated patients had renal failure. Conclusion: There is only weak evidence for the use of CDV. The intravesical admission route should be further investigated because of a good toxicity profile. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Probst, Kai A., Schmidt, Christian A., and Krüger, William
- Subjects
HYPOGONADISM ,STEM cell transplantation ,KALLMANN syndrome ,MEDICAL care ,STEM cells - Abstract
Objective: There is a substantial lack of data about men's health in adult allogeneic stem cell transplantation. Methods: We conducted prospective unicentric non-interventional clinical study on men's health with a follow-up time of 1 year. Results: Between 11/2013 and 12/2015, we were able to include 27 patients. AML was the most frequent underlying disease (25.9%), and we mainly used intermediate intense conditioning protocols (77.8%). Erectile dysfunction, loss of libido, and loss of efficiency were the most frequent symptoms of hypogonadism. At inclusion of the study, hypogonadism was already frequent. Primary hypogonadism was found in eight cases (29.6%) and secondary hypogonadism in one case (3.7%). We did not observe hypogonadism 6 months after inpatient treatment anymore, but there might still be the impairment of fertility because of still rising FSH levels at the end of the observation period. There were no significant associations of hypogonadism with myeloablative conditioning or kind of donor. Interestingly, there is a significant association with nicotine abuse (P = .049). Conclusions: On the whole, male hypogonadism was found in one-third of the patients who underwent allogeneic stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. No indication of increased infection rates using low‐dose alemtuzumab instead of anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis before allogeneic stem cell transplantation.
- Author
-
Neumann, Thomas, Schneidewind, Laila, Schmidt, Christian, Krüger, William, Thiele, Thomas, Pink, Daniel, and Schulze, Meike
- Subjects
ALEMTUZUMAB ,GRAFT versus host disease prevention ,EPSTEIN-Barr virus diseases ,STEM cell transplantation ,CYTOMEGALOVIRUS diseases ,THERAPEUTICS - Abstract
Abstract: Background: Alemtuzumab as part of the conditioning protocol is effective in reducing graft‐versus‐host disease (GvHD), but may be associated with increased infection rates, especially when using high doses (ie, 100 mg). Methods: We performed a retrospective, single‐center, case‐control study analyzing the rates of neutropenic fever, cytomegalovirus (CMV) reactivation, Epstein‐Barr virus (EBV) reactivation, clinical manifest toxoplasmosis, and clinical manifest human herpesvirus‐6 (HHV6) infection using low‐dose alemtuzumab in comparison with anti‐thymocyte globulin (ATG) as GvHD prophylaxis before allogeneic stem cell transplantation. Forty‐four patients transplanted from unrelated donors between 2001 and 2012 were matched by age, diagnosis, and conditioning regimen and treated either with alemtuzumab 10 mg at day −2 (respectively, 20 mg in case of mismatch transplantation) or ATG. ATG Fresenius (10 mg/kg for 3 days) or Thymoglobulin (2 mg/kg for 3 days) were used. Results: Rates of CMV reactivation, EBV reactivation, and clinical manifest HHV6 infection or toxoplasmosis did not differ significantly between both groups until 2 years after transplantation. No case of post‐transplant lymphoproliferative disorder was observed. Also, rates of neutropenic fever during inpatient treatment after transplantation did not differ significantly in both groups. Conclusion: We saw no indication of increased infections rates when using low‐dose alemtuzumab as GvHD prophylaxis before allogeneic stem cell transplantation in this retrospective analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
- Author
-
Schroeder, Thomas, Rautenberg, Christina, Krüger, William, Platzbecker, Uwe, Bug, Gesine, Steinmann, Juliane, Klein, Stefan, Hopfer, Olaf, Nachtkamp, Kathrin, Kondakci, Mustafa, Geyh, Stefanie, Haas, Rainer, Germing, Ulrich, Bornhäuser, Martin, and Kobbe, Guido
- Subjects
MYELODYSPLASTIC syndromes treatment ,ACUTE myeloid leukemia treatment ,DECITABINE ,STEM cell transplantation ,GRAFT versus host disease ,SALVAGE therapy ,PUBLIC health ,THERAPEUTICS ,ANTINEOPLASTIC agents ,GRAFT versus host disease prevention ,THERAPEUTIC use of antimetabolites ,COMPARATIVE studies ,RED blood cell transfusion ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,RESEARCH methodology ,MEDICAL cooperation ,MYELODYSPLASTIC syndromes ,RESEARCH ,SURVIVAL analysis (Biometry) ,DISEASE relapse ,EVALUATION research ,ACUTE myeloid leukemia ,TREATMENT effectiveness ,DISEASE remission ,RETROSPECTIVE studies ,AZACITIDINE - Abstract
In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far. We retrospectively analyzed data of 36 patients with hematological (n = 35) or molecular relapse (n = 1) of acute myeloid leukemia (AML, n = 29) or myelodysplastic syndrome (MDS, n = 7) collected from 6 German transplant centers. Patients were treated with a median of 2 cycles DAC (range, 1 to 11). DAC was the first salvage therapy in 16 patients (44%), whereas 20 patients (56%) had previously received 1 to 5 lines of salvage therapy including 16 of them had been treated with Aza. In 22 patients (61%), a median of 2 DLI per patient (range, 1 to 5) was administered in addition to DAC. As a result, overall response rate was 25% including 6 complete remissions (CR, 17%) and 3 partial remissions (PR, 8%). Three patients within the first-line group achieved CR, while also 3 patients receiving DAC as second-line treatment reached CR including 2 patients with previous Aza failure. Median duration of CR was 10 months (range, 2 to 33) and no patient relapsed so far. The 2-year OS rate was 11% (± 6%) without any difference between first-line and pretreated patients. Incidence of acute and chronic graft-versus-host disease was 19 and 5%. Taken together, DAC exerts clinical efficacy in patients with AML or MDS relapsing after allo-SCT and is able to induce durable remissions in individual patients suggesting that DAC may be an alternative to Aza or even a second choice after Aza failure. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab.
- Author
-
Neumann, Thomas, Plis, Andrzej, Weigel, Martin, Stracke, Sylvia, Friesecke, Sigrun, Stecher, Stephanie-Susanne, Schneidewind, Laila, Busemann, Christoph, Schmidt, Christian Andreas, and Krüger, William H.
- Subjects
CALCINEURIN ,ECULIZUMAB - Published
- 2017
- Full Text
- View/download PDF
19. Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation.
- Author
-
Busemann, Christoph, Jülich, Andreas, Buchhold, Britta, Schmidt, Vanessa, Schneidewind, Laila, Pink, Daniel, Schmidt, Christian, Neumann, Thomas, and Krüger, William
- Subjects
STEM cell transplantation ,DYSPNEA ,GRAFT versus host disease ,PALLIATIVE treatment ,PATIENTS ,THERAPEUTICS - Abstract
Purpose: Allogeneic stem cell transplantation may cure approximately 50% of patients, however, a significant part of the other half might benefit from a high-quality palliative care medicine at the end of life. Somatic, psychic and spiritual needs of these patients may differ from those of patients suffering from incurable solid tumours and are not comprehensively evaluated so far. Methods: To address this question, data from charts of 123 patients who have died after allogeneic stem cell transplantation were extracted. In detail, the time line of the clinical course, the symptoms, the administered drugs and other applied procedures were analysed. Results: Approximately one half of the patients, who have died after stem cell transplantation, did not live more than 5 months. Two-thirds of patients died within 14 months after SCT. 28.5% of the patients could not be discharged after transplantation. However, a significant proportion had a low ECOG-score (0-1) prior to death, indicating a high degree of mobility. Major symptoms were weakness, fatigue and need for aid at daily activities. Severe pain, dyspnoea and obstipation, as known from patients suffering from advanced solid tumours, were rare. In consequence, use of opioids seemed to be less frequent than in patients with solid tumours. Measures of intensive care and i.v.-drug administration were applied to a significant proportion of patients. Conclusion: The present investigation indicates that the somatic, psychic and spiritual end-of-life-care after allogeneic stem cell transplantation could be optimised. A significant problem for the transplantation team seems to be the realisation of necessity to switch the curative concept into a palliative ambition. Requirements are a subsequent prospectively conducted investigation and an intensification of cooperation between transplant and palliative care teams. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Rhabdomyolysis induced by nelarabine.
- Author
-
Späth, Christian, Schönau, Mandy, Gaubert, Sophie, Neumann, Thomas, Schmidt, Christian A., Heidel, Florian H., and Krüger, William H.
- Subjects
RHABDOMYOLYSIS ,BONE marrow cells - Abstract
4381549 8 Pandey RK, DiPippo A, Kadia T. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Computed tomography showed a complete remission after consolidation I and marrow cytology and histology were negative for T-LBL blasts. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
21. Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?
- Author
-
Schneidewind, Laila, Neumann, Thomas, Knoll, Florian, Zimmermann, Kathrin, Smola, Sigrun, Schmidt, Christian andreas, and Krüger, William
- Subjects
BK virus ,ALEMTUZUMAB ,CYTOMEGALOVIRUSES ,ANTINEOPLASTIC agents ,JOHN Cunningham virus ,GRAFT versus host disease ,STEM cell transplantation ,THERAPEUTICS - Abstract
Background: The association of polyomaviruses BK and JC with other opportunistic infections and graft-versus-host disease (GvHD) in allogeneic stem cell transplantation is controversially discussed. Methods: We conducted a retrospective study of 64 adult patients who received their first allogeneic stem cell transplantation between March 2010 and December 2014; the follow-up time was 2 years. Results: Acute leukemia was the most frequent underlying disease (45.3%), and conditioning included myeloablative (67.2%) and nonmyeloablative protocols (32.8%). All patients received 10 mg of alemtuzumab on day -2 (20 mg in case of mismatch) as GvHD prophylaxis. Twenty-seven patients (41.5%) developed cytomegalovirus (CMV) reactivation. BKPyV-associated hemorrhagic cystitis was diagnosed in 10 patients (15.6%). Other opportunistic infections caused by viruses or protozoa occurred rarely (<10%). There was no association of BKPyV or JCPyV with CMV reactivation, Epstein-Barr virus reactivation, human herpes virus 6, or parvovirus B19 infection requiring treatment. There was a significant correlation of BKPyV-associated hemorrhagic cystitis with toxoplasmosis (p = 0.013). Additionally, there was a significant link of simultaneous BKPyV and JCPyV viruria with toxoplasmosis (p = 0.047). BKPyV and JCPyV were not associated with GvHD, relapse, or death. Conclusion: We found no association of BKPyV or JCPyV with viral infections or GvHD. Only the correlation of both polyomaviruses with toxoplasmosis was significant. This is a novel and interesting finding. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Urological Complications and BK Virus-Associated Diseases Under Allogenic Stem Cell Transplantation.
- Author
-
Schneidewind, Laila, Neumann, Thomas, Burchardt, Martin, and Krüger, William
- Subjects
BK virus diseases ,STEM cell transplantation ,KIDNEY diseases ,CYSTITIS ,RETROSPECTIVE studies - Abstract
Every year 50,000 patients receive a stem cell transplantation worldwide, but there is lack of data pertaining to urological complications. Methods: We performed a retrospective analysis of all adult patients undergoing their first allogenic stem cell transplantation from January 2011 to June 2013 in our institution. Statistical tests performed were Pearson's correlation, chi-square testing and logistic regression using SPSS 22.0. Results: We identified 39 patients (22 males, 17 females). Twenty four patients (61.5%) had a urological complication. Most frequent urologic complications were bacterial urinary tract infection (n = 13; 33.3%), acute renal failure (n = 6; 15.4%) and BK virus-associated haemorrhagic cystitis (n = 5; 12.8%). BK viruria was detected in 12 patients (30.8%). We observed an association of creatinine increase (about 20 µmol/l at time of onset of BK viruria) with BK viruria (Pearson's correlation 0.64; p = 0.01), and BK viruria is significantly linked to acute renal failure (Pearson's correlation 0.35; p = 0.029). In univariate regression, BK viruria is significantly linked to urological complication (p = 0.025). Conclusions: We suggest that BK virus infection during stem cell transplantation can lead to BK virus associated nephropathy, which is so far only known from patients after kidney transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Is BK Virus-Associated Cystitis a Generalized Epithelial Disease?
- Author
-
Schneidewind, Laila, Neumann, Thomas, Zimmermann, Kathrin, Weigel, Martin, Schmidt, Christian Andreas, and Krüger, William
- Subjects
STEM cell transplantation ,BK virus ,CYSTITIS - Abstract
BK polyomavirus-associated haemorrhagic cystitis (BKHC) is a complication after allogeneic stem cell transplantation, which can occur in 5–60% of the cases. BK viruria alone can also occur in up to 100%. BKHC can lead to severe morbidity in stem cell-transplanted patients, but data about this disease is limited. Consequently, we conducted a prospective unicentric non-interventional trial on BKHC as well as BK viruria after first adult allogeneic stem cell transplantation with a follow-up time of 1 year after inpatient treatment. Between November 2013 and December 2015, we were able to include 40 adult patients with a mean age of 52.8 years. Twenty-seven (67.5%) of these patients were male and 13 (32.5%) were female. Acute myeloid leukaemia was the most frequent underlying disease (n = 15; 37.5%). Only 1 patient developed BKHC during inpatient treatment (n = 1; 2.5%), but BK viruria was frequent (n = 11; 27.5%) during inpatient treatment as well as in the follow-up time (n = 14; 35%). Interestingly, BK viruria was significantly associated with mucositis (p = 0.038) and number of transfused platelet concentrates (p = 0.001). This unexpected association will be discussed and needs further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.
- Author
-
Neumann, Thomas, Schneidewind, Laila, Thiele, Thomas, Schulze, Meike, Klenner, Anne, Busemann, Christoph, Pink, Daniel, Greinacher, Andreas, Dölken, Gottfried, and Krüger, William
- Subjects
BLOOD platelet transfusion ,STEM cell transplantation ,PLATELET count ,ALEMTUZUMAB ,C-reactive protein ,THERAPEUTICS - Abstract
Purpose: In patients undergoing allogeneic stem cell transplantation, conditioning regimens containing alemtuzumab instead of anti-thymocyte globulin (ATG) may result in an earlier platelet engraftment and a reduced number of platelet transfusions. Methods: We performed a retrospective, single-center, case-control study analyzing time to engraftment and transfusion needs using alemtuzumab in comparison with ATG as part of conditioning protocol. Results: Median values for time to platelet engraftment, number of transfused platelet concentrates and number of transfused red cell concentrates were 12 versus 19.5 days ( p < 0.001), 2 versus 14 ( p < 0.001) and 6 versus 14.5 ( p = 0.003) in the alemtuzumab and ATG group. Time to leukocyte engraftment did not differ with median 15 days in both groups. Patients in the ATG group showed a significant higher decrease in platelet count during conditioning (68 vs. 29 %, p = 0.001), leading to significant lower median platelet counts at the day of stem cell infusion (38 vs. 95.5 Gpt/l, p = 0.008), and higher values for median C-reactive protein after first antibody infusion (69.0 vs. 43.6 mg/l, p = 0.001) compared with alemtuzumab group. Test for significance was done by using Wilcoxon rank-sum test. Subgroup analysis considering the type of ATG used (Thymoglobulin vs. ATG Fresenius) revealed that differences between alemtuzumab and ATG group were more due to effects of ATG Fresenius than Thymoglobulin. Conclusions: The use of alemtuzumab in comparison with ATG as part of the conditioning regimen may be an approach to reduce the number of transfused platelet and red cell concentrates after allogeneic stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Treatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience.
- Author
-
Busemann, Christoph, Klein, Susanne, Schmidt, Christian, Evert, Matthias, Dölken, Gottfried, and Krüger, William
- Abstract
Prognosis of peripheral and other advanced T cell lymphomas is poor. 20 patients with a median age of 46.4 (range 20.5-64.1) years were treated with autoSCT ( n = 6) or alloSCT ( n = 14) from 1996 to 2013. All patients were at high risk either due to the IPI-score or to the fact that SCT was part of a salvage therapy. Conditioning prior to alloSCT was myeloablative in seven cases (50 %). The patients were pretreated with 8.5 (median, range 2-38) cycles of chemotherapy. Ten patients are alive in CR after a median follow-up of 1.3 years (range 0.1-13.3). OS was 53 % after one and 40 % after 10 years. Best survival was reached after related alloSCT (80 % at 10 years) compared to other modalities. GvHD did not influence survival. AlloSCT from related donors can cure patients from T-cell lymphomas. Unrelated alloSCT or high-dose therapy and autoSCT are an option for patients without a familiar donor. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI.
- Author
-
Späth, Christian, Busemann, Christoph, and Krüger, William
- Subjects
HEMATOPOIETIC stem cell transplantation ,IMMUNOSUPPRESSION ,CANCER prognosis ,CANCER patients ,HEALTH outcome assessment - Abstract
Introduction: Allogeneic stem cell transplantation (alloSCT) has become available for elderly patients or for patients with comorbidities by introduction of reduced-intense conditioning. Comorbidity-related prognosis after alloSCT can be estimated by the hematopoietic cell transplantation comorbidity index (HCT-CI). Material and Methods: The charts from 85 patients who have undergone 90 alloSCTs between 1999 and 2011 were analysed. Most patients received a dose-reduced conditioning and a graft from an unrelated donor. Patients were stratified for age, HCT-CI, cGvHD versus no cGvHD, and a modified HCT-CI with a further split high-risk score. Results: Age over 60 years did not affect the outcome. Manifestation of cGvHD improved the prognosis significantly. An additional stratification of the high-risk group of the HCT-CI revealed that even a fraction of these patients can have considerable benefit from an alloSCT. Furthermore, this high-risk collective could be clearly discriminated into two groups with different outcomes. Conclusions: The investigation confirms that age is no absolute risk factor for alloSCT and demonstrates the heterogeneity of the high-risk group of the HCT-CI. A comprehensive investigation of an additional stratification is suggested. Furthermore, the authors encourage early withdrawal of immunosuppression, even in elderly patients and patients with comorbidities to permit graft-versus-leukaemia/lymphoma, since cGvHD is associated with a significantly better prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
- Author
-
Krüger, William H, Hirt, Carsten, Basara, Nadezda, Sayer, Herbert G, Behre, Gerhard, Fischer, Thomas, Grobe, Norbert, Maschmeyer, Georg, Niederwieser, Dietger, and Dölken, Gottfried
- Published
- 2014
- Full Text
- View/download PDF
28. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO).
- Author
-
Krüger, William, Hirt, Carsten, Basara, Nadezda, Sayer, Herbert, Behre, Gerhard, Fischer, Thomas, Grobe, Norbert, Maschmeyer, Georg, Niederwieser, Dietger, and Dölken, Gottfried
- Subjects
STEM cell transplantation research ,CELL tumors ,CLINICAL trials ,CANCER chemotherapy ,CANCER remission ,CANCER treatment ,PATIENTS - Abstract
This study was conducted in order to evaluate allogeneic stem cell transplantation (alloSCT) as consolidation for patients with mantle cell lymphoma (MCL). Patients with MCL were included into two prospective trials OSHO #060 (refractory/relapsed) and #074 (de novo). Induction was rituximab and chemotherapy. Responding patients proceeded to alloSCT. Minimal residual disease was monitored by quantitative RT-PCR detecting either t(11;14) or clonospecific CDR-III regions. In case of circulating lymphoma cells, immunomodulation (cyclosporine A withdrawal, rituximab, donor lymphocyte infusion) was initiated. Thirty-three of 39 patients underwent alloSCT after myeloablative ( n = 7) or toxicity-reduced ( n = 26) conditioning. Leukocytes engrafted at day +16 (median, range 0-101) and platelets at day +14 (0-142). Acute graft-versus-host disease stages I-II occurred in 42 % and stages III-IV in 15 %. Five patients have relapsed after SCT. The overall mortality after SCT was 24 % ( n = 8). Median follow-up after SCT was 2.8 years (range 0.0-10.9). Five-year progression-free survival was 67 %, and overall survival 73 % after SCT. The results were comparable for primary MCL and refractory/relapsed disease as well as for related vs. unrelated SCT. Younger patients had a significantly better outcome than the elderly. AlloSCT is a feasible and promising consolidation therapy for relapsed and refractory disease and an attractive option for young patients with de novo MCL of high risk. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver, Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew, Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika
- Subjects
COMMUNICABLE disease treatment ,MYCOSES ,CANCER patients ,ANTIFUNGAL agents ,NEUTROPENIA ,HEMATOLOGY ,DISEASE risk factors - Abstract
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient's risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
30. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
- Author
-
Busemann, Christoph, Neumann, Thomas, Schulze, Meike, Klenner, Anne, Thiele, Thomas, Greinacher, Andreas, Dölken, Gottfried, and Krüger, William
- Subjects
ALEMTUZUMAB ,GRAFT versus host disease prevention ,STEM cell transplantation ,T cells ,THYMOCYTES ,GLOBULINS - Abstract
Antibody-mediated in vivo T cell depletion is common prior to unrelated (URD) or mismatched allogeneic stem cell transplantation (alloSCT) and optional in HLA-identical sibling (FAM) alloSCT. While anti-thymocyte globulin (ATG) is the current standard, alemtuzumab is an alternative. The optimal dose of alemtuzumab has not been defined. This retrospective analysis compares low-dose alemtuzumab with ATG in URD alloSCT and with no antibody in FAM alloSCT. Twenty-eight patients treated with alemtuzumab (10 mg; HLA mismatch, 20 mg) were matched to 28 patients who have either received ATG (URD) or no antibody (noAB) according to disease, disease stage, age, transplant type and risk state. Both groups were compared for engraftment, outcome, disease-free (DFS) and overall survival (OS), graft-versus-host disease (GvHD), freedom from GvHD (ffGvHD) and transplant-related mortality (TRM). No significant differences were found between the groups for leukocyte engraftment, GvHD, ffGvHD, TRM, DFS and OS. There was a trend for reduction of cGvHD by alemtuzumab ( p = 0.05). A transplant-type stratified subanalysis consolidated equivalency of alemtuzumab and ATG in URD-SCT and indicates possible superiority of low-dose alemtuzumab compared to noAB in FAM-SCT. Low-dose alemtuzumab, as part of conditioning regimen prior to alloSCT, is safe and comparable to standard ATG. Prospective trials, particularly comparing alemtuzumab vs. noAB in FAM alloSCT, should be conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Erdheim-Chester disease with hemophagocytosis.
- Author
-
Busemann, Christoph, Kallinich, Bianca, Schwesinger, Günther, Krüger, William, Schüler, Frank, Schmidt, Christian, Dölken, Gottfried, Schwesinger, Günther, Krüger, William, Schüler, Frank, Schmidt, Christian A, and Dölken, Gottfried
- Subjects
LETTERS to the editor ,HAEMOPHILUS diseases - Abstract
A letter to the editor is presented in response to previous issue concerning a 49-year old man who had Erdheim-Chester disease with hemophagocytosis in the June 2006.
- Published
- 2007
- Full Text
- View/download PDF
32. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Weissinger, Florian, Auner, Holger, Bertz, Hartmut, Buchheidt, Dieter, Cornely, Oliver, Egerer, Gerlinde, Heinz, Werner, Karthaus, Meinolf, Kiehl, Michael, Krüger, William, Penack, Olaf, Reuter, Stefan, Ruhnke, Markus, Sandherr, Michael, Salwender, Hans-Jürgen, Ullmann, Andrew, Waldschmidt, Dirk, and Wolf, Hans
- Subjects
ANTI-infective agents ,DENTAL prophylaxis ,FEBRILE seizures ,DRUG therapy ,HEMATOPOIETIC stem cell transplantation ,ONCOLOGY ,HEMATOLOGY - Abstract
More than 18,000 autolgous transplantation were performed in Europe in the year 2009. It as a routine procedure in experienced centres. Even if there is a low mortality rate, infections are a major issue after transplantation, occurring in more than 60 % of the patients. In this review we discuss all aspects of infections after autologous stem transplantation, including epidemiology, diagnostics, therapeutic algorithms, prophylaxis and supportive therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
33. Toxoplasmosis after allogeneic stem cell transplantation-a single centre experience.
- Author
-
Busemann, Christoph, Ribback, Silvia, Zimmermann, Kathrin, Sailer, Verena, Kiefer, Thomas, Schmidt, Christian, Schulz, Katrin, Steinmetz, Ivo, Dombrowski, Frank, Dölken, Gottfried, and Krüger, William
- Subjects
TOXOPLASMOSIS ,STEM cell transplantation ,DISEASE complications ,MULTIPLE myeloma ,MORTALITY ,MEDICAL imaging systems ,MAGNETIC resonance imaging ,IMMUNOSUPPRESSION ,DISEASE risk factors - Abstract
Toxoplasmosis is a rare but possibly underestimated complication following allogeneic stem cell transplantation with a high mortality rate. One reason might be the limitation of the diagnostic instruments relying mainly on imaging and molecular-based techniques. In this report, we present three cases of toxoplasmosis identified among 155 allograft recipients treated at Greifswald University Hospital. Widely disseminated toxoplasmosis was detected post-mortem in two patients allografted for high-risk multiple myeloma. Clinical signs suspicious for toxoplasmosis occurred after days +32 and +75, respectively. In one case, serology and conventional Toxoplasma gondii PCR, targeting the B1 gene, revealed negative results, while in the other patient, toxoplasmosis was not investigated. Both patients received pentamidine for Pneumocystis jirovecii pneumonia (PcP) prophylaxis. The third patient, a 68-year-old woman allografted for AML, developed cerebral toxoplasmosis from day +395 after allogeneic SCT with typical signs in magnetic resonance tomography. Toxoplasma DNA was amplified from one of two samples of cerebrospinal fluid. The patient died of disseminated toxoplasmosis despite immediate initiation of therapy. Retrospective comparative testing of clinical specimens by the conventional T. gondii PCR and by a real-time PCR targeting a 529-bp genomic fragment suggests a higher sensitivity of the latter method in our patients. In conclusion, we suggest a rigorous real-time PCR monitoring for high-risk patients or patients with signs of infections suspicious for toxoplasmosis, even though low-copy results are presently difficult to interpret. Our reported cases might also encourage the use of trimethoprim-sufmethoxazole instead of pentamidine for PcP prophylaxis in those patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
- Author
-
Thiele, Thomas, Krüger, William, Zimmermann, Kathrin, Ittermann, Till, Wessel, Antje, Steinmetz, Ivo, Dölken, Gottfried, and Greinacher, Andreas
- Subjects
CYTOMEGALOVIRUS diseases ,BLOOD products ,NUCLEIC acids ,IMMUNOGLOBULIN G ,HEMATOPOIETIC stem cell transplantation - Abstract
BACKGROUND: Measures to prevent transfusion-transmitted cytomegalovirus (TT-CMV) infection after hematopoietic stem cell transplantation (HSCT) include transfusion of CMV antibody-negative blood units and/or transfusion of leukoreduced cellular blood products. We assessed the incidence of TT-CMV in CMV-seronegative patients receiving CMV-seronegative HSC transplants, who were transfused with leukoreduced cellular blood products not tested for anti-CMV. STUDY DESIGN AND METHODS: In a prospective observational study between 1999 and 2009, all HSCT patients received leukoreduced cellular blood products not tested for anti-CMV. Patients were screened for CMV serostatus and CMV-negative recipients of CMV-negative transplants were systematically monitored for TT-CMV clinically and by CMV nucleic acid testing. Anti-CMV antibodies (immunoglobulin [Ig]G and IgM) were assessed after three time intervals (Interval 1, study inclusion to Day +30 after HSCT; Interval 2, Day +30-Day +100; Interval 3, after Day +100). RESULTS: Among 142 patients treated with allogeneic HSCT, 23 CMV-negative donor-patient pairs were identified. These 23 patients received 1847 blood products from 3180 donors. All patients remained negative for CMV DNA and none developed CMV-associated clinical complications. This results in a risk for TT-CMV per donor exposure of 0% (95% confidence interval, 0.0%-0.12%). However, 17 of 23 patients seroconverted for anti-CMV IgG, but none for anti-CMV IgM. CMV IgG seroconverters received significantly more transfusions per week than nonconverters. CONCLUSION: The risk of TT-CMV is low in high-risk CMV
neg/neg HSCT patients transfused with leukoreduced blood products not tested for anti-CMV. The cause of anti-CMV IgG seroconversion is most likely passive antibody transmission by blood products. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
35. Mucositis after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation.
- Author
-
Busemann, Christoph, Wilfert, Hanna, Neumann, Thomas, Kiefer, Thomas, Dölken, Gottfried, and Krüger, William H.
- Published
- 2011
- Full Text
- View/download PDF
36. Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation.
- Author
-
Krüger, William H., Kiefer, Thomas, Daeschlein, Georg, Steinmetz, Ivo, Kramer, Axel, and Dölken, Gottfried
- Subjects
AMINOGLYCOSIDES ,TUMOR treatment ,ANTIBIOTICS ,ANTIBIOSIS ,AUTOGRAFTS ,FEVER ,HEMATOPOIETIC stem cell transplantation ,HOMOGRAFTS ,INFECTION ,T-test (Statistics) ,U-statistics ,DISEASE incidence ,RETROSPECTIVE studies ,DATA analysis software ,ANTIBIOTIC prophylaxis ,THERAPEUTICS - Abstract
Copyright of GMS Krankenhaushygiene Interdisziplinaer is the property of German Medical Science Publishing House gGmbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
37. Rectal Intussusception due to Re-Recurrent Ovarian Fibrosarcoma.
- Author
-
Langner, Inga, Glitsch, Anne, Krüger, William, Vogelgesang, Silke, Langner, Sönke, von Bernstorff, Wolfram, and Heidecke, Claus-Dieter
- Published
- 2009
- Full Text
- View/download PDF
38. Myocardial and aortal involvement in a case of disseminated infection with Fusarium solani after allogeneic stem cell transplantation: report of a case.
- Author
-
Busemann, Christoph, Krüger, William, Schwesinger, Günther, Kallinich, Bianca, Schröder, Gudrun, Abel, Peter, Kiefer, Thomas, Neumann, Thomas, and Dölken, Gottfried
- Subjects
FUSARIOSIS ,PRECANCEROUS conditions ,SKIN infections ,MYOCARDIAL infarction ,AORTIC diseases ,STEM cell transplantation - Abstract
We describe a 57-year-old woman suffering from acute erythroblastic leukaemia. After the first course of high-dose Ara-C containing consolidation therapy, the patient developed multiple skin lesions on the left foot. A skin biopsy revealed a Fusarium infection. The lesions regressed under therapy with caspofungin and voriconazole. Leukaemia relapsed after 1 year and an allogeneic stem cell transplantation was performed for consolidation of leukaemia in second remission. Again, the patient developed macular skin lesions located on the trunk and the extremities with central pallor. Clinical examination showed fever, tachyarrhythmia and a systolic murmur. Fusarium spp. was cultured from blood samples. An antimycotic therapy with amphotericin B, voriconazole and posaconazole failed completely. The patient died in a septic shock with consecutive multiple organ failure. The autopsy (SN 1/06, Institute of Pathology, University of Greifswald) revealed a disseminated infiltration with Fusarium solani including myocardial, endocardial and aortal infection. The involvement of the cardiovascular system is uncommon in fusariosis and has not been described so far. This case confirms other reports describing the high mortality of fusariosis after allogeneic stem cell transplantation. A rapid diagnosis and antimycotics with higher activity against Fusarium spp. are necessary for successful therapy of this severe mould infection in the immunocompromised host. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
39. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Cornely, Oliver, Einsele, Herrmann, Enzensberger, Ruxandra, Hebart, Holger, Heinz, Werner, Junghanss, Christian, Karthaus, Meinolf, Krüger, William, Krug, Utz, Kubin, Thomas, Penack, Olaf, Reichert, Dietmar, Reuter, Stefan, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew, and Maschmeyer, Georg
- Subjects
MYCOSES ,ANTIFUNGAL agents ,CANCER patients ,MORTALITY ,AMPHOTERICIN B ,ASPERGILLOSIS - Abstract
Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
40. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte–colony-stimulating factor in patients with primary central nervous system lymphoma.
- Author
-
Kiefer, Thomas, Krüger, William H., Montemurro, Michael, Schüler, Frank, Hirt, Carsten, Pasold, Rita, Niederwieser, Dietger, Schwenke, Matthias, and Dölken, Gottfried
- Subjects
STEM cells ,LYMPHOMAS ,HEMAPHERESIS ,METHOTREXATE ,GRANULOCYTES - Abstract
BACKGROUND: High-dose therapy with autologous stem cell support after standard dose induction is a promising approach for therapy of primary central nervous system lymphoma (PCNSL). High-dose methotrexate (HD-MTX) is a standard drug for induction of PCNSL; however, data about the capacity of HD-MTX plus granulocyte–colony-stimulating factor (G-CSF) to mobilize hemopoietic progenitors are lacking. STUDY DESIGN AND METHODS: This investigation describes the data from stem cell mobilization and apheresis procedures after one or two cycles of HD-MTX for induction of PCNSL within the East German Study Group for Haematology and Oncology 053 trial. Eligible patients proceeded to high-dose busulfan/thiotepa after induction therapy and mobilization. RESULTS: Data were available from nine patients with a median age of 58 years. The maximal CD34+ cell count per µL of blood after the first course of HD-MTX was 13.89 (median). Determination was repeated in six patients after the second course with a significantly higher median CD34+ cell count of 33.69 per µL. Five patients required two apheresis procedures and in four patients a single procedure was sufficient. The total yield of CD34+ cells per kg of body weight harvested by one or two leukapheresis procedures was 6.60 × 10
6 (median; range, 2.68 × 106 -15.80 × 106 ). The yield of CD34+ cells exceeded the commonly accepted lower threshold of 3 × 106 cells per kg of body weight in eight of nine cases. Even in the ninth, hemopoietic recovery after stem cell reinfusion was rapid and safe. CONCLUSION: HD-MTX plus G-CSF is a powerful combination for stem cell mobilization in patients with PCNSL and permits safe conduction of time-condensed and dose-intense protocols with high-dose therapy followed by stem cell reinfusion after HD-MTX induction. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
41. Hygienic safety of reusable tap water filters (Germlyser) with an operating time of 4 or 8 weeks in a haematological oncology transplantation unit.
- Author
-
Daeschlein, Georg, Krüger, William H., Selepko, Christian, Rochow, Markus, Dölken, Gottfried, and Kramer, Axel
- Subjects
WATER filtration ,FILTERS & filtration ,DRINKING water purification ,DRINKING water microbiology ,PATHOGENIC microorganisms ,MICROBIAL contamination ,SANITARY microbiology - Abstract
Background: Microbial safe tap water is crucial for the safety of immunosuppressed patients. Methods: To evaluate the suitability of new, reusable point-of-use filters(Germlyser®, Aquafree GmbH, Hamburg, Germany), three variations of a reusable filter with the same filter principle but with different outlets (with and without silver) and inner surface coating of the filter encasements (with and without nano-crystalline silver) were tested. The filter efficacy was monitored over 1, 4 and 8 weeks operating time in a haematological oncology transplantation unit equipped with 18 water outlets (12 taps, 6 showers). Results: The filtered water fulfilled the requirements of absence of pathogens over time. From 348 samples, 8 samples (2.3%) exceeded 100 cfu/ml (no sample = 500 cfu/ml). As no reprocessed filter exhibited 100% filter efficacy in the final quality control after each reprocessing, these contaminations could be explained by retrograde contamination during use. Conclusion: As a consequence of the study, the manufacturer recommends changing filters after 4 weeks in high risk areas and after 8 weeks in moderate infectious risk areas, together with routine weekly alcohol-based surface disinfection and additionally in case of visible contamination. The filter efficacy of the 3 filters types did not differ significantly regarding total bacterial counts. Manual reprocessing proved to be insufficient. Using a validated reprocessing in a washer/disinfector with alkaline, acid treatment and thermic disinfection, the filters were effectively reprocessable and now provide tap water meeting the German drinking water regulations as well as the WHO guidelines, including absence of pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
42. Haemopoietic Cell Transplantation of Patients with a History of Deep or Invasive Fungal Infection during Prophylaxis with Liposomal Amphotericin B.
- Author
-
Krüger, William H., Rüssmann, Bettina, De Wit, Maike, Kröger, Nicolaus, Renges, Helmut, Sobottka, Ingo, and Zander, Axel R.
- Subjects
STEM cell transplantation ,ASPERGILLOSIS ,CANDIDIASIS ,IMMUNOSUPPRESSION ,CELL transplantation ,MYCOSES ,HOMOGRAFTS - Abstract
Relapse of a preceding fungal infection is a considerable risk during haemopoietic stem cell transplantation. The optimal secondary prophylaxis has not been found so far since the application of standard drugs is hampered by potential ineffectiveness or intolerable side effects. This investigation describes haemopoietic cell transplantation of patients with a history of invasive or systemic fungal infection (IFI). The strategy was either administration of liposomal amphotericin B as secondary prophylaxis or an early switch to liposomal amphotericin B after administration of azoles. The 43 patients had a history of proven (n = 14), probable (n = 14) and possible (n = 15) IFI. Twenty-eight patients (65%) could be discharged from the BMT ward without signs of mycosis. Transplant-related mortality was 35%. Overall, 12 fungus-related (IFI) deaths (28%) occurred. The percentage of fungus-related deaths was highest in the ‘proven’ group with 43% compared to 20 and 21% in the two other groups. Side effects of liposomal amphotericin B were low. A discontinuation of the drug was not necessary in any patient. Serum creatinine showed a slight increase to 128% (median) of the baseline allowing continuous administration of concomitant nephrotoxic drugs such as cyclosporin A. In conclusion, secondary prophylaxis with or early switch to liposomal amphotericin B facilitates allogeneic stem cell transplantation of patients with a history of IFI with minor side effects. However, fungal infections and transplant-related mortality remain major problems in this often heavily pretreated subgroup of patients. Copyright © 2005 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
43. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Einsele, Hermann, Bertz, Hartmut, Beyer, Jörg, Kiehl, Michael G., Runde, Volker, Kolb, Hans-Jochen, Holler, Ernst, Beck, Robert, Schwerdfeger, Rainer, Schumacher, Ulrike, Hebart, Holger, Martin, Hans, Kienast, Joachim, Ullmann, Andrew J., Maschmeyer, Georg, Krüger, William, Niederwieser, Dietger, Link, Hartmut, Schmidt, Christian A., and Oettle, Helmut
- Subjects
BONE marrow transplantation ,STEM cell transplantation ,EPIDEMIOLOGY ,DISEASES - Abstract
The risk of infection after allogeneic stem cell transplantation is determined by the underlying disease, the intensity of previous treatments and complications that may have occurred during that time, but above all, the risk of infection is determined by the selected transplantation modality (e.g. HLA-match between the stem cell donor and recipient, T cell depletion of the graft, and others). In comparison with patients treated with high-dose chemotherapy and autologous stem cell transplantation, patients undergoing allogeneic stem cell transplantation are at a much higher risk of infection even after hematopoietic reconstitution, due to the delayed recovery of T and B cell functions. The rate at which immune function recovers after hematopoietic reconstitution greatly influences the incidence and type of post-transplant infectious complications. Infection-associated mortality, for example, is significantly higher following engraftment than during the short neutropenic period that immediately follows transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
44. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Cornely, Oliver A., Böhme, Angelika, Buchheidt, Dieter, Glasmacher, Axel, Kahl, Christoph, Karthaus, Meinolf, Kern, Winfried, Krüger, William, Maschmeyer, Georg, Ritter, Jörg, Salwender, Hans J., Sandherr, Michael, Schiel, Xaver, Schüttrumpf, Silke, Sieniawski, Michal, Silling, Gerda, Ullmann, Andrew J., and Wolf, Hans-Heinrich
- Subjects
MYCOSES ,AMPHOTERICIN B ,TUMORS ,NEUTROPENIA - Abstract
Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogeneic stem cell transplant recipients are at particularly high risk for invasive fungal infections. Other well described risk factors are neutropenia >10 days, corticosteroid therapy, sustained immunosuppression, graft versus host disease, and concomitant viral infections. The enormous study efforts are contrasted by a scarcity of risk stratified evidence based recommendations for clinical decision making. The objective of this review accumulating information on about 10.000 patients is to assess evidence based criteria primarily regarding the efficacy of antifungal prophylaxis in neutropenic cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
45. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
- Author
-
Kröger, Nicolaus, Zabelina, Tatjana, Krüger, William, Renges, Helmut, Stute, Norbert, Schrum, Johanna, Kabisch, Hartmut, Schafhausen, Philippe, Jaburg, Nicole, Löliger, Cornelius, Schäfer, Peter, Hinke, Axel, and Zander, Axel R.
- Subjects
CYTOMEGALOVIRUSES ,STEM cell transplantation ,T cells - Abstract
We evaluated the cytomegalovirus (CMV) serostatus as a risk factor for survival and treatment-related mortality (TRM) in 125 patients allografted from an unrelated donor between 1994 and 1999. All patients received pretransplant in vivo T-cell depletion using rabbit anti-thymocyte globulin (ATG). Only one patient had primary graft failure and severe grade III/IV graft-versus-host disease occurred in 14% of the patients. The overall survival (OS) at 3 years was 70% for CMV-negative patients (n = 76) and 29% in the seropositive cohort (n = 49) (P > 0·001). In multivariate analyses, CMV seropositivity remained an independent negative prognostic factor for OS (RR: 2·1; CI: 1·2–3·8; P = 0·014), apart from age > 20 years (RR: 2·74; CI: 1·2–3·8; P = 0·004) and late leucocyte engraftment (RR: 2·4; CI: 1·2–4·9; P = 0·015). The TRM for all patients was 27%. Despite monitoring for CMV antigenaemia and preemptive therapy with ganciclovir when reactivation occurred, seropositive patients had a three times higher risk of fatal treatment-related complications than seronegative patients. In multivariate analyses, CMV seropositivity remained the strongest independent negative factor for TRM (RR: 5·3; CI: 1·9–14·6; P = 0·002), followed by age > 20 years (RR: 4·8; CI: 1·3–18·1; P = 0·02) and delayed leucocyte engraftment (RR: 3·6; CI: 1·2–11; P = 0·02). The TRM was identical in seropositive patients with (n = 27) or without (n = 22) CMV reactivation (44% versus 50%). We conclude that CMV seropositivity, despite preemptive ganciclovir therapy and even without reactivation, is a major negative prognostic factor for survival as well as for TRM in unrelated stem cell transplantation using pretransplant in vivo T-cell depletion with ATG. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
46. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
- Author
-
Kröger, Nicolaus, Zabelina, Tatjana, Krüger, William, Renges, Helmut, Stute, Norbert, Dürken, Matthias, Graf von Finkenstein, Friedrich, Erttmann, Rolf, Kabisch, Hartmut, Schafhausen, Philipe, Jaburg, Nicole, Löliger, Cornelius, Zander, Axel R, Kröger, N, Zabelina, T, Krüger, W, Renges, H, Stute, N, Dürken, M, and Graf von Finkenstein, F
- Subjects
GRAFT versus host disease ,STEM cells ,TRANSPLANTATION of organs, tissues, etc. ,MYELOID leukemia ,GLOBULINS ,ORGAN donation - Abstract
To reduce the incidence of GvHD and the rate of graft failure in unrelated stem cell transplantation, we incorporate anti-thymocyte globulin in the preparative regimen in 98 patients with hematological or inherited storage disease. The median age was 32 years (range: 1-56) and 84 patients underwent transplantation from HLA-A,-B and DR identical donor, while in 14 patients the donor were mismatched either in HLA- A, -B or -DR locus. Only one patient with chronic myelocytic leukemia (CML) and blast crisis had a primary graft failure (1%). Grade II-IV acute GvHD occurred in 37 patients (37%), grade III/IV GvHD developed in 15 patients (15%). Chronic GvHD was observed in 29%, and only 12 patients had extensive GvHD (17%). After a median follow-up of 34 months (range, 9-90), the estimated overall survival at 3 years for all patients is 58% (CI 95%: 48%-68%), and the estimated disease-free survival at 3 years is 49% (CI 95%: 38%-60%). For patients with CML transplanted in first chronic phase or accelerated phase (n=40), the estimated overall survival at 3 years is 70% (CI 95%: 56%-84%), and the estimated disease-free survival at 3 years is 58% (CI 95%: 17%-85%). ATG in unrelated stem cell transplantation reduces the risk of severe acute and chronic GvHD and of graft failure without an obvious increase of severe infection. Further follow-up is mandatory to determine the incidence of late relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
47. Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells.
- Author
-
Krüger, William, Jung, Roman, Detlefsen, Birte, Mumme, Sandra, Badbaran, Anita, Brandner, Johanna, Renges, Helmut, Kröger, Nicolaus, Zander, Axel, Krüger, W H, Jung, R, Detlefsen, B, Mumme, S, Badbaran, A, Brandner, J, Renges, H, Kröger, N, and Zander, A R
- Subjects
CANCER diagnosis ,DNA analysis ,CANCER ,COMPARATIVE studies ,CYTOSKELETAL proteins ,DIAGNOSTIC errors ,GENES ,GLYCOPROTEINS ,RESEARCH methodology ,MEDICAL cooperation ,METASTASIS ,POLYMERASE chain reaction ,PROTEINS ,RESEARCH ,RNA ,TUMOR markers ,EVALUATION research ,REVERSE transcriptase polymerase chain reaction ,CANCER cell culture ,STANDARDS ,DIAGNOSIS - Abstract
Several reverse-transcriptase polymerase chain reaction (rtPCR) assays have been designed for the detection of disseminated cancer cells. The specificity of these discussed molecular approaches is controversial. Biological interference of the cytokeratin-20 and mammaglobin rtPCR assays has been investigated. Cell lines of different lineages and bone marrow and peripheral stem cells from patients without epithelial cancer have been examined for the transcription of the cytokeratin-20 (CK20) and mammaglobin messages prior to and after stimulation with different cytokines in a total of 370 liquid cultures. Amplification of both messages from clinical samples prior to stimulation does not support the high specificity for the detection of disseminated epithelial cancer cells as reported. Cytokeratin-20 was amplified from the chronic myeloic leukemia (CML)-derived line K562. Transcription was not influenced by cytokines, either in cell-line experiments or in clinical samples. The thesis of a low-level background transcription in granulocytes is supported. Mammaglobin was induced in cell lines significantly by GM-CSF and in clinical samples additionally by several more cytokines. These results indicate that under certain conditions involving cytokine production, the use of mammaglobin rtPCR for the detection of epithelial cancer cells could be limited. In conclusion, the mechanism of interference of both rtPCR assays are completely different and further research is necessary before the cytokeratin-20 or mammaglobin rtPCR could become standard methods for the detection of disseminated epithelial cancer cells. These factors leading to so-called false-positive results have to be considered in future applications of rtPCR for the detection of minimal residual disease. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
48. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
- Author
-
Kröger, Nicolaus, Renges, Helmut, Krüger, William, Gutensohn, Kai, Löliger, Cornelius, Carrero, Isabel, Cortes, Lourdes, and Zander, Axel R.
- Subjects
GRANULOCYTES ,FILGRASTIM ,STEM cells ,HEMAPHERESIS ,GRAFT versus host disease ,TRANSPLANTATION of organs, tissues, etc. - Abstract
To evaluate the schedule dependency of granulocyte colony-stimulating factor (G-CSF) (filgrastim) for stem cell mobilization, we conducted a randomized comparison in 50 healthy donors, with one subcutaneous daily injection of 10 µg/kg G-CSF (n = 25) compared with twice injections daily of 5 µg/kg G-CSF (n = 25). The two groups were well balanced for age, body weight and sex. G-CSF application was performed on an out-patient basis and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were mild to moderate bone pain (88%), mild headache (72%), mild fatigue (48–60%) and nausea (8%) without differences between the two groups. The CD34
+ cell count in the first apheresis was 5·4 × 106 /kg donor weight (range 2·8–13·3) in the 2 × 5 µg/kg group compared with 4·0 × 106 /kg (range 0·4–8·8) in the 1 × 10µg/kg group (P = 0·007). The target of collecting > 3·0 × 106 CD34+ cells/kg donor weight with one apheresis procedure was achieved in 24/25 (96%) donors in the 2 × 5 µg/kg group and in 17/25 (68%) donors in the 1 × 10 µg/kg group. The target of collecting > 5·0 × 106 CD34+ cells/kg in the first apheresis was achieved in 64% in the 2 × 5µg/kg group, but in only 36% in the 1 × 10 µg/kg group. The progenitor cell assay for granulocyte–macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) was higher in the 2 × 5 µg/kg group than in the 1 × 10 µg/kg group (7·0 vs. 3·5 × 105 /kg, P = 0·01; 6·6 vs. 5·0 × 105 /kg; P = 0·1). Administering G-CSF (filgrastim) at a dosage of 5 µg/kg twice daily rather than 10 µg/kg once daily is recommended; this leads to a higher CD34+ cell yield and requires fewer apheresis procedures without increasing toxicity or cost. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
49. Significance of BK Polyomavirus in Long-Term Survivors after Adult Allogeneic Stem Cell Transplantation.
- Author
-
Neumann, Thomas, Peters, Nandette, Kranz, Jennifer, Dräger, Desiree L., Heidel, Florian H., Krüger, William, and Schneidewind, Laila
- Subjects
STEM cell transplantation ,POLYOMAVIRUSES ,CHRONIC kidney failure ,SURVIVAL rate ,KIDNEY physiology - Abstract
Simple Summary: Allogeneic stem cell transplantation is a curative treatment option for several hematological diseases. Data about health status and late complications of long-term survivors of this therapy are limited, so we conducted a prospective study. This analysis focusses on kidney function and urological complications. Interestingly, the BK polyomavirus plays an important role in this patient population and can lead to severe impairment of kidney function. This was only previously described in the acute situation following transplantation. Further studies should address causal therapy development for this severe viral infection. Background: Allogeneic stem cell transplantation (aSCT) is a common treatment for a variety of hematological diseases. Advances in transplantation practices have led to an increasing number of long-term aSCT survivors, but data about health status and late complications are sparse. This analysis focusses on kidney function and urological complications in this population. Methods: This study is a prospective unicentric non-interventional trial. Before starting the study, we obtained the approval of the local ethics review board. Furthermore, the study was registered at WHO Clinical Trial Registry. The study protocol is available via UTN. Results: We were able to include 33 patients with a mean age of 60.5 years (SD 11.1). The median survival time following allogeneic stem cell transplantation was 9.0 years (IQR 8.5–13.0). Five patients (15.2%) had BKPyV viruria with mean 218.3 (SD 674.2) copies/mL. BKPyV viruria was significantly linked to pre-existing chronic kidney failure (p = 0.019), creatine > 100 µmol/L (p < 0.001), and cystatin c > 1.11 mg/L (p = 0.021), respectively. We were not able to identify a single risk factor for BKPyV viruria in univariate or multivariate Cox regression. Conclusions: BKPyV-associated nephropathy might be one reason for impaired kidney function in long-term survivors of aSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer.
- Author
-
Krüger, William, Tögel, Florian, Kröger, Nicolaus, Rössing, Sabine, Gieseking, Friederike, Gutensohn, K, Lindner, Christoph, Jänicke, Fritz, Zander, Axel, Krüger, W, Tögel, F, Kröger, N, Rössing, S, Gieseking, F, Lindner, C, Jänicke, F, and Zander, A R
- Subjects
BIOTHERAPY ,BREAST tumors ,GRANULOCYTE-colony stimulating factor ,IMMUNOHISTOCHEMISTRY ,LEUKAPHERESIS ,POLYMERASE chain reaction ,PROTEINS ,REVERSE transcriptase polymerase chain reaction ,MONONUCLEAR leukocytes - Abstract
Peripheral blood stem cells were mobilised with G-CSF from steady-state haemopoiesis after previous anthracyclin-containing standard dose chemotherapy in patients with high-risk breast cancer. 48 samples were obtained from patients with stage II–III breast cancer and ≥10 lymph nodes, 15 samples from patients with chemotherapy sensitive metastatic disease, and 13 samples from women with inflammatory breast cancer. 44 samples were first or single leukaphereses and 32 samples were second or third harvests. Aliquots were searched for contaminating tumour cells by immunocytochemistry (IC) and cytokeratin-19 reverse transcriptase polymerase chain reaction (rtPCR). The median count of MNCs examined by IC was 2×10
6 ; cDNA prepared from 2×107 cells was subjected to PCR. Fifty-nine samples were examined by immunocytochemistry, 36 samples by rtPCR, and 19 samples by both techniques. Samples investigated by IC and rtPCR were judged as positive if there was at least one positive test. On the whole, 42/79 (55.3%) of the samples were positive with an insignificant trend to a higher positivity rate in second or subsequent leukaphereses (52.3% vs 59.3%). The median tumour cell load per 106 MNCs was low with 0.5(0–7) cells in all, and a total of 2.2 (0.5–7) cells in positive specimen. Differences in the cancer cell load of first and subsequent leukaphereses and between subgroups of patients were not found. PCR and IC gave consistent results in 63.2%. This phenomenon can be explained by the greater sensitivity of the molecular method and by a Poisson distribution of coharvested tumour cells in samples. Tumour cell contamination in G-CSF mobilised stem cells from patients with breast cancer from steady state haemopoiesis after preceding anthacyclin-containing chemotherapy is frequent, but the tumour cell load is low. To allow a comparison of different studies dealing with cancer cell contamination in stem cells, standardisation of assays is necessary. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.